Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT536 Monotherapy and Combinations in Advanced Solid Tumors
NCT05395052Phase 1Terminated
- Sponsor
- Fate Therapeutics
- Start
- May 2022
- Primary completion
- Aug 2023
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of FT536 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer and 5 more (6 arms), sponsored by Fate Therapeutics. Primary endpoints: Recommended Phase 2 Dose at 3 years and Number of Participants with Adverse Events at 3 years. Started May 2022; status: terminated.
02
Drugs
FT536
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)breast cancerovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05395052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395052.